Gilead Sciences, Inc.’s Quad Pill Raises Kidney Questions, FDA Says

Gilead Sciences Inc. (GILD)s experimental HIV pill Quad may need additional monitoring because of kidney damage seen in studies, U.S. regulators said. The four-in-one combination pill from Gilead, the…
Read the full story: BioSpace.com Featured News